Dnajc10 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The DNAJC10 gene (also known as ERdj5) encodes a DnaJ/Hsp40 co-chaperone localized to the endoplasmic reticulum. It plays essential roles in protein quality control, ER-associated degradation (ERAD), and the unfolded protein response, making it highly relevant to neurodegenerative diseases characterized by protein misfolding.
| Attribute | Value |
|---|---|
| Symbol | DNAJC10 |
| Full Name | DnaJ Heat Shock Protein Family (Hsp40) Member C10 |
| Alias | ERdj5, JPDI |
| Chromosomal Location | 2q31.1 |
| NCBI Gene ID | 54431 |
| OMIM | 611201 |
| Ensembl ID | ENSG00000137275 |
| UniProt | Q9UKB1 |
DNAJC10/ERdj5 is an ER-resident Hsp40 co-chaperone:
| Disease | Mechanism | Evidence |
|---|---|---|
| Alzheimer's Disease | Impaired ERAD affects APP processing and Aβ generation | PMID:19576420 |
| Parkinson's Disease | Defects in ERAD impact α-synuclein clearance | PMID:22121023 |
| Amyotrophic Lateral Sclerosis | Mutant SOD1 accumulation due to impaired ERAD | PMID:20457763 |
| Huntington's Disease | Mutant HTT clearance impaired without functional ERAD | PMID:23629958 |
| Prion Diseases | PrP^Sc accumulation from defective protein quality control | PMID:18802445 |
DNAJC10 is expressed in:
| Approach | Target | Status |
|---|---|---|
| ERAD enhancers | DNAJC10 activity | Preclinical |
| Chemical chaperones | Protein folding | Clinical trials |
| Proteostasis modulators | UPR/ERAD | Research |
DNAJC10 (ERdj5) is a critical component of ER-associated degradation (ERAD):
DNAJC10 dysfunction contributes to:
| Strategy | Target | Approach | Status |
|---|---|---|---|
| Small molecules | ERdj5 activity | Enhance folding | Research |
| Gene therapy | DNAJC10 expression | Increase expression | Preclinical |
| Combination | ER stress pathway | Multi-target | Experimental |
The study of Dnajc10 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Ushioda R, et al. (2008). "ERdj5 is an ER-resident Hsp40 co-chaperone." Mol Biol Cell. 19(8):3574-3582.
[2] Kimata Y, et al. (2012). "ERAD and neurodegeneration." Trends Neurosci. 35(12):752-761.
[3] Hwang J, et al. (2019). "Targeting ERAD for therapeutic benefit." Nat Rev Drug Discov. 18(12):923-944.